Picture of Vaxcyte logo

PCVX — Vaxcyte News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapNeutral

Vaxcyte Inc expected to post a loss of $1.17 a share - Earnings Preview

* Vaxcyte Inc  PCVX.OQ   PCVX.O  is expected to show no
change in
quarterly revenue when it reports  results on May 6 (estimated)
for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Vaxcyte Inc is for a
loss of
$1.17 per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 6.6%
in the last three months. ​
    * Wall Street's median 12-month price target for Vaxcyte Inc
is
$102.00​, above​ its last closing price of $65.96. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -1.11       -1.07      -1.82     Missed  -69.8
 Jan. 1 2023   -0.84       -0.84      -0.91     Missed  -8.7
 Jun. 30 2023  -0.75       -0.74      -0.70     Beat    6​
 Mar. 31 2023  -0.84       -0.83      -0.70     Beat    15.2
 ​​Dec.        -0.98       -0.93      -1.02     Missed  -9.7
 31 2022                                                
 Sep. 30 2022  -0.84       -0.84      -0.93     Missed  -11.2​
 Jan. 1 0001   -0.69       -0.69      -0.80     Missed  -15.9
 Jan. 1 0001   -0.64       -0.63      -0.68     Missed  -8.5
 This summary was machine generated May 4 at 02:02 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Vaxcyte

See all news